YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
45 hedge funds and large institutions have $222M invested in Y-mAbs Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
45
Holders Change
+3
Holders Change %
+7.14%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
13
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.57M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.82M |
| 4 |
BlackRock
New York
|
+$716K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$715K |
Top Sellers
| 1 |
SCM
Scopia Capital Management
New York
|
-$17.5M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$6.31M |
| 3 |
Millennium Management
New York
|
-$2.66M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.02M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$994K |
